Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 2/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | CKS1B | P61024 | 1/20 | 0.31 |
| ▸ | SKP1 | P63208 | 1/20 | 0.31 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 6/20 | 0.31 |
| ▸ | APP | P05067 | 5/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720827 | 0.78 | L3MBTL1 (0.33) | BACE1APPBACE2CTSD | |
| SCHEMBL28890112 | 0.77 | PDK2 (0.43) | PDK2GBA1CKS1BSKP1SKP2 | |
| SCHEMBL13408567 | 0.77 | PDK2 (0.42) | PDK2GBA1AAK1CHEK2KAT6A | |
| SCHEMBL10665148 | 0.75 | PDK2 (0.39) | PDK2GBA1AAK1CACNA1GCACNA1B | |
| SCHEMBL8516151 | 0.75 | BACE1 (0.43) | BACE1APPBACE2CHEK2CTSD | |
| SCHEMBL18291610 | 0.74 | PDK2 (0.42) | PDK2GBA1AAK1CACNA1GCACNA1B | |
| SCHEMBL14720653 | 0.74 | BACE1 (0.41) | BACE1APPBACE2CTSD | |
| SCHEMBL14720961 | 0.74 | BACE1 (0.42) | BACE1APPBACE2CTSD | |
| SCHEMBL31351970 | 0.73 | PDK2 (0.39) | PDK2GBA1AAK1CACNA1GCACNA1B | |
| SCHEMBL31482453 | 0.73 | PDK2 (0.39) | PDK2GBA1AAK1CACNA1GCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3023423-B1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | NOVARTIS AG (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-3023423-A1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-9163011-B2 | Oxazine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | disclosed |
| US-20150150877-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| EP-2748162-A1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | Novartis AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-20130172331-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG | 2013-07-04 | — | — | US | disclosed |
| WO-2013027188-A1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | NOVARTIS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172331-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BACE2, BACE1, PSEN1 | PDK2 435/4885GBA1 32/4885AAK1 662/4885 |
| US-20150150877-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BACE2, BACE1, PSEN1 | PDK2 435/4885GBA1 32/4885AAK1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.